Grifols (GRFS) Research & Development (2010 - 2018)
Grifols' (GRFS) quarterly Research & Development came in at -$203.5 million in Q2 2018, down 396.6% YoY from $68.6 million in Q2 2017, and down 396.6% on a QoQ basis from $68.6 million in Q2 2017.
Grifols (GRFS) Research & Development (2010 - 2018) Analysis & Trends
Grifols (GRFS) has 9 years of Research & Development data on file, last reported at -$203.5 million in Q2 2018.
- Quarterly Research & Development fell 396.6% year-over-year to -$203.5 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $298.5 million (down 46.52% YoY) and the FY2025 annual result came in at $495.9 million, up 20.85% from the prior year.
- Research & Development fell to -$203.5 million in Q2 2018, from $68.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $375.0 million in Q4 2016 to a low of -$203.5 million in Q2 2018.
- A 5-year average of $50.2 million and a median of $56.3 million in 2014 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2015 — Research & Development jumped 90200.9% — and 2018, when it tumbled 396.6%.
- Tracing GRFS's Research & Development over 5 years: stood at $56.3 million in 2014, then advanced by 28.7% to $72.4 million in 2015, then jumped by 417.84% to $375.0 million in 2016, then slumped by 81.7% to $68.6 million in 2017, then plunged by 396.6% to -$203.5 million in 2018.
- The last three Research & Development figures came in at -$203.5 million (Q2 2018), $68.6 million (Q2 2017), and $375.0 million (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.98 Bn | 627.22 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 466.45 Bn | 459.88 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 372.04 Bn | 364.90 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 299.31 Bn | 291.62 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 256.25 Bn | 251.35 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 235.50 Bn | 221.52 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 159.26 Bn | 147.56 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 104.79 Bn | 100.62 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Grifols | 5.49 Bn | 4.48 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -203.52 Mn |
| Jun 30, 2017 | 68.62 Mn |
| Dec 31, 2016 | 374.96 Mn |
| Sep 30, 2016 | 58.39 Mn |
| Jun 30, 2016 | 56.14 Mn |
| Dec 31, 2015 | 72.41 Mn |
| Sep 30, 2015 | 60.28 Mn |
| Jun 30, 2015 | 58.59 Mn |
| Mar 31, 2015 | -57.53 Mn |
| Dec 31, 2014 | 56.26 Mn |
| Sep 30, 2014 | 56.20 Mn |
| Jun 30, 2014 | 64,888.16 |
| Mar 31, 2014 | 51.93 Mn |
| Dec 31, 2013 | 45.27 Mn |
| Sep 30, 2013 | 42.12 Mn |
| Jun 30, 2013 | 38.08 Mn |
| Mar 31, 2013 | 38.70 Mn |
| Dec 31, 2012 | 35.47 Mn |
| Sep 30, 2012 | 39.60 Mn |
| Jun 30, 2012 | 39.02 Mn |